Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

Lung cancer patients can expect improved long term survival under a new treatment combination, according to new Irish ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients ...

Prof Patrick Forde of the Trinity St James’s Cancer Institute presented the findings at the latest meeting of the American ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

The American Cancer Society says more people are surviving cancer, and a new study estimates there are 18.6 million people in the U.S. living with a history of cancer as of Jan 1. By the year 2035, ...

Survival rates for stage 3 non-small cell lung cancer (NSCLC) range from as high as 36% to as low as 13%, depending on the subtype. There is also a five-year survival rate of 18% for small cell ...

prostate cancer often progresses slowly and has one of the highest survival rates among all types of cancer. A five-year prostate cancer survival rate tells us the percentage of people with the ...

Survival rates for stage 3 non-small cell lung cancer (NSCLC) range from as high as 36% to as low as 13%, depending on the subtype. There is also a five-year survival rate of 18% for small cell lung ...